期刊文献+

含有对氨基苯甲酸和苯磺酰胺结构单元的新型分子及其抗糖尿病活性 被引量:9

Synthesis and Antidiabetic Activity of Novel Molecules Containing p-Aminobenzoic Acid and Benzenesulfonamide Moiety
原文传递
导出
摘要 基于本实验室前期发现的高活性分子的结构特征,作者设计了含有对氨基苯甲酸和苯磺酰胺结构单元的新型分子.通过4条合成路线的探索,发现了中间体IM1~IM3及目标分子TM1和TM2的简捷合成路线和实用合成方法;采用本实验室前期建立的合成方法,顺利得到设计的26个化合物,合成方法简便,反应条件温和,收率为64%~95%.21个新化合物通过1H NMR,13C NMR和HRMS进行结构表征.目前的体外抗糖尿病活性结果显示,所得26个分子的过氧化物酶体增殖物激活受体(PPAR)的激动活性较弱.本研究进一步证实了醇/二氯亚砜体系脱除脂肪酰芳胺酰基的能力,有助于含有对氨基苯甲酸和苯磺酰胺结构单元分子的进一步结构优化. A new class of target molecules containing p-aminobenzoic acid and benzenesulfonamide moiety is reported, based on the structural features of a series of analogues with strong biological activities previously synthesized by the group. By taking 4 discrete synthetic routes, the practical procedures and facile preparative routes for both the intermediates of IMI-IM3 and the target molecules of TM1 and TM2 were established. A total of 26 designed compounds were synthesized smoothly using the established synthetic approaches under mild reaction conditions, with low cost and high yields (64%-95%). The chemical structures of 21 new compounds were confirmed by IH NMR, 13C NMR and HRMS techniques. The bio- assay test demonstrates weak antidiabetic activity for all the target molecules. This study has further expanded the application of alcohol/SOC12 system in the deacylation of N-arylacetamides and chloro-N-arylacetamides as well as esterification of car- boxy group concomitantly, which is supportive to the structure optimization of novel molecules containing p-aminobenzoic acid and benzenesulfonamide moiety.
出处 《有机化学》 SCIE CAS CSCD 北大核心 2012年第10期1908-1918,共11页 Chinese Journal of Organic Chemistry
基金 重庆市科技攻关计划(Nos.2011AB5001 2011AC1053 2011AC5107)资助项目~~
关键词 糖尿病 对氨基苯甲酸 磺胺 过氧化物酶体增殖物激活受体 合成 活性 diabetes mellitus p-aminobenzoic acid sulfanilamide peroxisome proliferator-activated receptors (PPAR) syn- thesis activity
  • 相关文献

参考文献2

二级参考文献32

  • 1赵明,彭师奇,迪丽努尔,王银叶,周琴璐,赵文忠.含 RGD 四肽的合成与功能[J].药学学报,1997,32(4):271-277. 被引量:18
  • 2De Clercq, E. Expert Opin. Emerg. Drugs 2005, 10, 241.
  • 3Mastrolorenzo, A.; Rusconi, S.; Scozzafava, A.; Supuran, C. T. Expert Opin. Ther. Pat. 2006, 16, 1067.
  • 4Supuran, C. T.; Innocenti, A.; Mastrolorenzo, A.; Scozzafava, A. Min. Rev. Med. Chem. 2004, 4, 189.
  • 5Louis, J. M.; Clore, G. M.; Gronenborn, A. M. Nat. Struct. Biol. 1996, 6, 868.
  • 6Freire, E. Drug Discovery Today: Disease Mechanisms 2006, 3, 281.
  • 7Ohtaka, H.; Velazquez-Campoy, A.; Xie, D.; Freire, E.Protein Sci. 2002, 11, 1908.
  • 8Shidhaye, S. S.; Hemant, P.; Majid, H.; Kadam, V. Curr. Drug Ther. 2,007, 2, 111.
  • 9Ghosh, A. K.; Sridhar, P. R.; Leshchenko, S.; Hussain, A. K.; Li, J.; Kovalevsky, A. Y.; Walters, D. E.; Wedekind, J. E.; Grum-Tokars, V.; Das, D.; Koh, Y.; Maeda, K.; Gatanaga, H.; Weber, I. T.; Mitsuya, H. J. Med. Chem. 2006, 49, 5252.
  • 10Ghosh, A. K.; Kincaid, J. F.; Cho, W.; Waiters, D. E.; Krislman, K.; Hussain, K. A.; Koo, Y.; Cho, H.; Rudall, C.; Holland, L.; Buthod, J. Bioorg. Med. Chem. Lett. 1998, 8, 687.

共引文献15

同被引文献67

引证文献9

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部